# Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

> **NCT07738276** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Heart Failure and Reduced Ejection Fraction
- Obesity & Overweight
- Tirzepatide

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07738276
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-18
- **Primary completion:** 2027-06-11
- **Final completion:** 2027-12-22
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738276, "Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07738276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*